Journal
FUNDAMENTAL & CLINICAL PHARMACOLOGY
Volume 32, Issue 5, Pages 462-484Publisher
WILEY
DOI: 10.1111/fcp.12373
Keywords
anticancer drugs; cannabidiol; cannabinol; cannabis; herbal-drug interaction; tetrahydrocannabinol
Categories
Ask authors/readers for more resources
Cannabis is a plant that has been used for centuries to relieve a wide range of symptoms. Since the 1960s, interest in medical research into this plant has grown steadily. Already very popular for recreational use, a growing number of consumers not accustomed to using cannabis for psychoactive purposes have begun to use it as an alternative or complement to mainstream pharmaceutical medicines. The principal unsubstantiated or social' uses of cannabis are based mainly on data that is at best controversial, but usually not scientifically proven. The aim of this review was to identify the scientific basis and reasons that lead patients with cancer to consume cannabis, and also to identify whether there is a risk of interaction between cannabis and anticancer medicines through drug transporters (P-glycoprotein and other ATP-binding cassette superfamily members) Cytochromes P450 (3A, 1A, 2B, 2C, 2D families...) and glucuronyl transferases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available